Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.

Rotstein Grein, Ingrid HertaPinto, Natalia FerreiraLobo, AlineGroot, NoortjeSztajnbok, Flavioda Silva, Clóvis Artur AlmeidaPaim Marques, Luciana BAppenzeller, SimoneIslabão, Aline GarciaMagalhães, Claudia Saadde Almeida, Rozana GasparelloBica, BlancaFraga, Melissada Fraga, Aline Coelho MoreiraDos Santos, Maria CarolinaRobazzi, TeresaTerreri, Maria Teresa RaBandeira, MarciaPasmans, HellaSchepp, Rutgervan der Klis, Fionade Roock, SytzeWulffraat, NicoPileggi, Gecilmara2020-07-092020-07-092020-07-011477-09623250117210.1177/0961203320928406http://hdl.handle.net/10029/623897eninfo:eu-repo/semantics/closedAccessSystemic lupus erythematosusautoimmune diseasesdisease activityvaccinationSafety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.ArticleLupus 2020; 29(8):934-42